MAP2K7 and familial atrioventricular septal defect: The consensus guidelines for the treatment of ECD recommend BRAF inhibitors as the first‐line treatment for BRAFV600E‐mutant ECD and recommend MEK inhibitors for ECD harboring another MAPK/ERK pathway mutation [1].